Achaogen Inc (NASDAQ:AKAO) has been given an average rating of “Hold” by the fifteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $5.71.
A number of equities research analysts have recently issued reports on AKAO shares. ValuEngine raised shares of Achaogen from a “sell” rating to a “hold” rating in a research note on Friday, September 7th. SunTrust Banks reduced their price target on shares of Achaogen from $16.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, August 20th. Zacks Investment Research raised shares of Achaogen from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Wednesday, October 10th. Mizuho reissued a “neutral” rating and issued a $8.00 price target on shares of Achaogen in a research note on Tuesday, November 6th. Finally, HC Wainwright reissued a “neutral” rating and issued a $3.00 price target (down from $19.00) on shares of Achaogen in a research note on Monday, November 12th.
In other Achaogen news, major shareholder Robert W. Duggan acquired 80,175 shares of the company’s stock in a transaction that occurred on Friday, November 23rd. The stock was purchased at an average price of $1.89 per share, for a total transaction of $151,530.75. Following the completion of the acquisition, the insider now owns 8,343,945 shares of the company’s stock, valued at approximately $15,770,056.05. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Robert W. Duggan acquired 157,760 shares of the company’s stock in a transaction that occurred on Tuesday, November 27th. The stock was acquired at an average price of $1.79 per share, with a total value of $282,390.40. Following the acquisition, the insider now directly owns 8,343,945 shares of the company’s stock, valued at approximately $14,935,661.55. The disclosure for this purchase can be found here. Insiders purchased 242,583 shares of company stock valued at $441,451 in the last 90 days. Company insiders own 7.80% of the company’s stock.
Several hedge funds have recently made changes to their positions in AKAO. Paloma Partners Management Co acquired a new position in Achaogen during the 3rd quarter worth approximately $174,000. Jefferies Group LLC acquired a new position in Achaogen during the 3rd quarter worth approximately $275,000. Point72 Asset Management L.P. acquired a new position in Achaogen during the 3rd quarter worth approximately $399,000. Sei Investments Co. acquired a new position in Achaogen during the 2nd quarter worth approximately $423,000. Finally, Gamco Investors INC. ET AL grew its holdings in Achaogen by 84.2% during the 3rd quarter. Gamco Investors INC. ET AL now owns 174,400 shares of the biopharmaceutical company’s stock worth $696,000 after acquiring an additional 79,700 shares in the last quarter. Hedge funds and other institutional investors own 45.59% of the company’s stock.
Shares of Achaogen stock traded down $0.09 on Monday, reaching $1.39. The company had a trading volume of 623,913 shares, compared to its average volume of 857,306. The company has a market capitalization of $68.26 million, a price-to-earnings ratio of -0.44 and a beta of 0.52. Achaogen has a 52-week low of $1.36 and a 52-week high of $15.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.52 and a current ratio of 2.54.
Achaogen Company Profile
Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.
See Also: Cost of Capital
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.